Targets & Mechanisms: Heart cells: no longer undivided 

 

Table 1. Cardiovascular expressions. At least 10 companies have gene therapies in preclinical through Phase III development to treat a range of cardiovascular indications. The majority of the gene therapies act by promoting angiogenesis or improving the function of existing heart cells. Only one therapy-VN-100 from VentriNova Inc.-regenerates heart tissue by promoting the proliferation of existing cardiomyocytes.
Source: BCIQ: BioCentury Online Intelligence

Company

Product

Description

Indication(s)

Status

Cardium Therapeutics Inc. (OTCQB:CRXM)

Generx alferminogene tadenovec (Ad5FGF4)

Adenoviral vector encoding fibroblast growth factor 4 (FGF4)

Coronary artery disease (CAD); ischemia/reperfusion injury

Phase III

Vical Inc. (NASDAQ:VICL); AnGes MG Inc. (Tokyo:4563); Daiichi Sankyo Co. Ltd. (Tokyo:4568); Mitsubishi Tanabe Pharma Corp. (Tokyo:4508)

Collategene beperminogene perplasmid (AMG0001; HGF gene therapy)

Plasmid encoding human hepatocyte growth factor/scatter factor (HGF/SF)

Advanced peripheral artery disease (PAD); ischemia/reperfusion injury

Phase III

Celladon Corp. (NASDAQ:CLDN); AmpliPhi Biosciences Corp. (OTCBB:APHB)

Mydicar (AAV1/SERCA2a)

Recombinant adeno-associated viral (AAV) vector encoding ATPase Ca++ transporting cardiac muscle slow
twitch 2
(ATP2A2; SERCA2A)

Heart failure

Phase IIb

Advanced heart failure in patients with a left ventricular assist device (LVAD); diastolic heart failure; pulmonary arterial hypertension (PAH); arteriovenous fistula maturation failure in dialysis patients

Preclinical

ViroMed Co. Ltd. (KOSDAQ:084990)

VM202

Proprietary pCK vector encoding engineered HGF/SF

Ischemia/reperfusion injury

Phase II

CAD

Phase I/II

VentriNova Inc.

VN-100

Adenoviral vector encoding cyclin A2 (CCNA2)

Myocardial infarction (MI)

Preclinical

NanoCor Therapeutics Inc.

Carfostin

Protein phosphatase 1 regulatory inhibitor subunit 1A (PPP1R1A) delivered via biological nanoparticle technology

Congestive heart failure (CHF)

Preclinical